News | Cardiac Imaging | October 21, 2019

Greater Left Ventricular Mass Increases Risk of Heart Failure

Swiss study uses 15-year MRI data to assess likelihood of coronary artery disease-related death and heart failure

Greater Left Ventricular Mass Increases Risk of Heart Failure

October 21, 2019 — Elevated left ventricular mass, known as left-ventricular hypertrophy, is a stronger predictor of coronary artery disease-related death and heart failure than coronary artery calcium score, according to a new study published in the journal Radiology.[1]

In the study led by Nadine Kawel-Boehm, M.D., a senior staff radiologist at Hospital Graubünden in Chur, Switzerland, a team of researchers analyzed data collected in the Multi-Ethnic Study of Atherosclerosis (MESA) sponsored by the National Heart, Lung and Blood Institute. MESA is an ongoing, multi-center study of a diverse, population-based sample of 6,814 men and women age 45-84 with no known heart disease.

According to Kawel-Boehm, there is little research on predicting the long-term risk of cardiovascular events in ethnically diverse patients who have magnetic resonance imaging (MRI)-identified left ventricular (LV) hypertrophy, a condition in which the muscle mass of the heart’s main pumping chamber is increased.

“Previous studies have used ECG or echocardiography, which have lower sensitivity in the diagnosis of LV hypertrophy, and typically follow patients for only several years,” she said. “The MESA study used MRI, which is the gold standard for quantifying LV mass, and had a long follow-up of 15 years.”

The researchers studied otherwise healthy individuals from the community in the MESA study.   4,988 MESA participants underwent a baseline cardiac MRI between 2000 and 2002 and participated in follow-up over a 15-year period. MRI showed that 247 participants in the study group had LV hypertrophy.

The mean age of all participants at baseline was 62 years, and 52 percent were women. Thirty-nine percent were white, 13 percent were Asian, 26 percent were African American and 22 percent were Hispanic.

At the 15-year follow-up, the research team found that 290 patients had a significant coronary heart disease (CHD) event, including 207 myocardial infarctions (heart attacks) and 95 CHD deaths. Cardiovascular disease-related deaths occurred in 57 patients, and 215 patients had heart failure.

A statistical analysis of the data demonstrated that LV hypertrophy was an independent predictor of significant CHD events, including myocardial infarction, coronary artery disease-related death and heart failure.

According to the analysis, 22 percent of the study participants with LV hypertrophy had a significant CHD event, compared to 6 percent of participants without LV hypertrophy.

Patients with LV hypertrophy had 4.3 times the risk of coronary artery disease-related death compared to participants without LV hypertrophy. Deaths from coronary and non-coronary related cardiovascular causes were more strongly related to LV hypertrophy than to coronary artery calcium scoring done with a CT scan.

“In contrast to the widely used coronary artery calcium by CT, which measures a condition not known to regress under medical therapy, an elevated LV mass is potentially reversible under treatment,” Kawel-Boehm said.

As a result of the long length of the study follow-up, Kawel-Boehm said the researchers were able to determine that the risk of cardiovascular events began to increase in participants with LV hypertrophy particularly after five years.

“Our results provide further evidence and motivation for regular follow up and management of individuals with left ventricular hypertrophy,” she said. “A higher LV mass quantified by imaging may matter more in some instances than a high calcium score.”

For more information: www.pubs.rsna.org/journal/radiology

 

Reference

1. Kawel-Boehm N., Kronmal R., Eng J., et al. Left Ventricular Mass at MRI and Long-term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA). Radiology, published online Aug. 27, 2019. doi: 10.1148/radiol.2019182871

Related Content

Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
MR Solutions cryogen free preclinical MRI
News | Magnetic Resonance Imaging (MRI) | January 09, 2020
January 9, 2020 — MR Solutions is continuing to expand its support network
The study found that DBN laws helped some women understand they had increased breast density, but not that breast density is associated with a higher risk of breast cancer or that dense breasts limit the ability of mammograms to detect cancer
News | Breast Density | January 09, 2020
January 9, 2020 — A new study suggests that state-mandated notifications on...
prostate cancer UCL study
News | Prostate Cancer | January 03, 2020
January 3, 2020 — Nearly one in six deaths from...
Videos | MRI Breast | December 26, 2019
Gillian Newstead, M.D., director of global breast imaging and former professor at the University of Chicago, explains